{"id":"placebo-ziltivekimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL4297732","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T12:51:05.151795","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ziltivekimab binds to and neutralizes IL-6, a key pro-inflammatory cytokine involved in systemic inflammation and cardiovascular disease. By blocking IL-6, the drug aims to reduce inflammatory markers and potentially improve cardiovascular outcomes in patients with elevated inflammatory burden.","oneSentence":"Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:29:04.450Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cardiovascular disease with elevated inflammatory markers (Phase 3 development)"}]},"_fixedFields":["pubmed(9)"],"trialDetails":[{"nctId":"NCT07276282","phase":"PHASE3","title":"Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction","status":"RECRUITING","sponsor":"ECRI bv","startDate":"2025-12-19","conditions":"Coronary Artery Disease, Acute Myocardial Infarction (AMI), Coronary Atherosclerosis of Native Coronary Artery","enrollment":332},{"nctId":"NCT07301034","phase":"PHASE3","title":"A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-12-18","conditions":"Myocardial Infarction","enrollment":332},{"nctId":"NCT05636176","phase":"PHASE3","title":"A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2023-05-08","conditions":"Heart Failure","enrollment":5600},{"nctId":"NCT06200207","phase":"PHASE3","title":"A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-04-01","conditions":"Heart Failure, Systemic Inflammation","enrollment":680},{"nctId":"NCT05379829","phase":"PHASE1","title":"A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-05-30","conditions":"Chronic Kidney Disease and Systemic Inflammation","enrollment":24},{"nctId":"NCT06118281","phase":"PHASE3","title":"ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-06-25","conditions":"Cardiovascular Risk, Acute Myocardial Infarction (AMI)","enrollment":10000},{"nctId":"NCT03926117","phase":"PHASE2","title":"Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-06-03","conditions":"Chronic Kidney Diseases, Inflammation","enrollment":264},{"nctId":"NCT05021835","phase":"PHASE3","title":"ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2021-08-30","conditions":"Cardiovascular Risk, Chronic Kidney Disease, Inflammation","enrollment":6200},{"nctId":"NCT06263244","phase":"PHASE3","title":"Specifying the Anti-inflammatory Effects of Ziltivekimab","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2024-05-03","conditions":"Atherosclerosis, Inflammation","enrollment":40},{"nctId":"NCT04626505","phase":"PHASE2","title":"Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-22","conditions":"Chronic Kidney Disease, Inflammation, Cardiovascular Risk","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"recentPublications":[{"date":"2026 Jan 1","pmid":"41369941","title":"Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction.","journal":"JAMA cardiology"},{"date":"2024 Dec 19","pmid":"39699771","title":"\"Anti-inflammatory Therapies in Atherosclerosis - Where are we going?\".","journal":"Current atherosclerosis reports"},{"date":"2024 Jan 1","pmid":"38088558","title":"Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE).","journal":"Journal of the American Society of Nephrology : JASN"},{"date":"2023 Oct","pmid":"37211246","title":"Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial.","journal":"Journal of cardiology"},{"date":"2023 Feb 1","pmid":"36449307","title":"Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical Trial.","journal":"JAMA cardiology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (ziltivekimab)","genericName":"Placebo (ziltivekimab)","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation. Used for Cardiovascular disease with elevated inflammatory markers (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}